<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370548</url>
  </required_header>
  <id_info>
    <org_study_id>DARE-BV1-001</org_study_id>
    <nct_id>NCT04370548</nct_id>
  </id_info>
  <brief_title>DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)</brief_title>
  <official_title>A Phase 3 Multi-Center, Double-Blind, Placebo-Controlled, Randomized Study of DARE-BV1 in the Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daré Bioscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daré Bioscience, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study of DARE-BV1&#xD;
      (clindamycin phosphate vaginal gel, 2%) (QD x 1 day) compared to placebo vaginal gel (HEC&#xD;
      Universal Placebo Gel) (QD × 1 day) for the treatment of bacterial vaginosis. Patients will&#xD;
      be evaluated at three time points: a Day 1 Screening/Randomization visit, a Day 7-14 Interim&#xD;
      Assessment visit, and a Day 21 - 30 Test of Cure [TOC] visit). Patients who discontinue&#xD;
      prematurely from the study will receive a safety follow-up phone call between Day 21-30. The&#xD;
      total study duration will be approximately one month for each individual patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Actual">December 7, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients will be randomly assigned to one of the following treatment groups (2:1): DARE- BV1 clindamycin phosphate vaginal gel, 2% (1 dose is 5 g gel = 100 mg clindamycin) QD × 1 day, or placebo vaginal gel (Universal HEC Placebo Gel), 5g, QD × 1 day. Study drug will be applied intravaginally within 1 day of randomization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cure</measure>
    <time_frame>Visit 3 Day 21-30 post randomization</time_frame>
    <description>The primary efficacy endpoint is the proportion of patients with Clinical Cure at the TOC visit (Day 21-30). Clinical cure is defined as:&#xD;
Resolution of the abnormal vaginal discharge associated with BV;&#xD;
Negative 10% KOH &quot;whiff test;&quot; and&#xD;
Clue cells &lt; 20% of the total epithelial cells in the saline wet mount.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Clinical Cure at the Interim Assessment Visit (Day 7-14).</measure>
    <time_frame>Visit 2 Day 7-14 post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Bacteriological Cure at the TOC Visit (Day 21-30). Bacteriological Cure is Defined as a Nugent Score &lt; 4</measure>
    <time_frame>Visit 3 Day 21-30 post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Bacteriological Cure at Interim Assessment Visit, Day 7-14</measure>
    <time_frame>Visit 2, Days 7-14 post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Therapeutic Cure at the TOC Visit (Day 21-30).</measure>
    <time_frame>Visit 3 Day 21-30 post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Therapeutic Cure at the Interim Assessment Visit (Day 7-14).</measure>
    <time_frame>Visit 2 Day 7-14 post randomization</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of Patients With Clinical Cure at the Test of Cure Visit (21-30)</measure>
    <time_frame>Visit 3, Days 21-30 post randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Patients With Clinical Cure at Interim Assessment Visit, Days 7-14, PP Population</measure>
    <time_frame>Visit 2, Days 7-14 post randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Patients With Bacteriological Cure at Test of Cure Visit, Days 21-30, PP Population</measure>
    <time_frame>Visit 3, Days 21-30 post randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Patients With Bacteriological Cure, Interim Assessment Visit, Days 7-14, PP Population</measure>
    <time_frame>Visit 2, Days 7-14 post randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Patients With Therapeutic Cure at Test of Cure Visit, Days 21-30; PP Population</measure>
    <time_frame>Visit 3, Days 21-30 post randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Patients With Therapeutic Cure, Interim Assessment Visit, Days 7-14, PP Population</measure>
    <time_frame>Visit 2, Days 7-14 post randomization</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Clindamycin phosphate vaginal gel, 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo vaginal gel (Universal HEC Placebo Gel)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DARE-BV1clindamycin phosphate vaginal gel, 2%</intervention_name>
    <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
    <arm_group_label>Clindamycin phosphate vaginal gel, 2%</arm_group_label>
    <arm_group_label>Placebo vaginal gel (Universal HEC Placebo Gel)</arm_group_label>
    <other_name>Placebo vaginal gel (HEC Universal Placebo Gel)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants must provide written informed consent prior to any study-related&#xD;
             procedures being performed. Patients from 12 through 17 years old may participate&#xD;
             where permitted by applicable local regulations and Institutional Review Board (IRB)&#xD;
             approval and with appropriate documentation of consent from the parent(s)/guardian(s)&#xD;
             and assent from the patient.&#xD;
&#xD;
          2. Participants must have a clinical diagnosis of bacterial vaginosis, defined as having&#xD;
             all of the following:&#xD;
&#xD;
               1. Off-white (milky or gray), thin, homogeneous discharge with minimal or absent&#xD;
                  pruritus and inflammation of the vulva and vagina&#xD;
&#xD;
               2. The presence of clue cells &gt; 20% of the total epithelial cells on microscopic&#xD;
                  examination of the saline wet mount&#xD;
&#xD;
               3. Vaginal secretion pH of &gt; 4.5&#xD;
&#xD;
               4. A fishy odor of the vaginal discharge with the addition of a drop of 10% KOH&#xD;
                  (i.e., a positive &quot;whiff test&quot;)&#xD;
&#xD;
          3. Participants must be females ≥ 12 years of age with no known medical conditions that,&#xD;
             in the Investigator's opinion, may interfere with study participation.&#xD;
&#xD;
          4. Participants must agree to abstain from sexual intercourse and/or sexual activity&#xD;
             throughout the first seven days following treatment. Patients must also agree to use&#xD;
             adequate birth control (see Inclusion Criterion #5) should they later engage in&#xD;
             heterosexual intercourse through the final study visit (Day 21-30).&#xD;
&#xD;
          5. Participants of childbearing potential must have a negative urine pregnancy test&#xD;
             result at screening, should use adequate birth control after the first seven days of&#xD;
             treatment if engaging in heterosexual intercourse, and should not plan on becoming&#xD;
             pregnant for the duration of the study. Acceptable forms of birth control include oral&#xD;
             contraceptives (the pill), intrauterine devices (IUDs), contraceptive implants under&#xD;
             the skin, patches or injections, and non-polyurethane condoms (e.g., latex,&#xD;
             polyisoprene) with or without spermicide. Patients in monogamous relationships with&#xD;
             vasectomized males may also participate. Abstinence may be allowed, but requires&#xD;
             Medical Monitor (or designee) approval prior to randomization. Oral or transdermal&#xD;
             hormonal contraceptives must be in use for one full cycle (e.g., four to eight weeks)&#xD;
             prior to study drug application. Injectable or implanted contraceptives (e.g.,&#xD;
             Depo-Provera, Nexplanon, or hormonal IUD) must be injected/inserted at least seven&#xD;
             days prior to study drug application. Participants who are not of childbearing&#xD;
             potential, as defined below, must also have a negative urine pregnancy test prior to&#xD;
             randomization:&#xD;
&#xD;
               1. Postmenopausal for at least one year prior to the Entry Visit (Visit 1) (defined&#xD;
                  as amenorrheic for more than one continuous year), or&#xD;
&#xD;
               2. Surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy,&#xD;
                  or hysterectomy) at least 6 months before first dose, or&#xD;
&#xD;
          6. Non-surgical permanent sterilization procedure at least 3 months prior to first dose.&#xD;
&#xD;
          7. Participants must be willing to refrain from the use of all intra-vaginal products&#xD;
             (e.g., douches, feminine deodorant sprays, condoms, spermicides, vaginal moisturizers&#xD;
             and lubricants, tampons, vaginal birth control rings [e.g., NuvaRing®], and&#xD;
             diaphragms) through the first 7 days at a minimum, and ideally through Visit 3 (Day&#xD;
             21-30) or Study Exit/Early Discontinuation.&#xD;
&#xD;
          8. Participants must be able to read, write, and understand English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with active vulvovaginitis or other active infectious causes of cervicitis,&#xD;
             vaginitis, or vulvitis (e.g., candidiasis, Trichomonas vaginalis, Chlamydia&#xD;
             trachomatis, Neisseria gonorrhoeae, or genital lesions or ulcers consistent with human&#xD;
             papillomavirus, active Herpes simplex, syphilis, chancroid, etc.).&#xD;
&#xD;
          2. Potential participants who are pregnant or breastfeeding, or if of child-bearing&#xD;
             potential unwilling to practice acceptable means of birth control or abstinence during&#xD;
             the study as described above.&#xD;
&#xD;
          3. Patients with a vaginal, vulvar, or genitourinary condition that, according to the&#xD;
             Investigator's judgement, may confound the interpretation of clinical response.&#xD;
&#xD;
          4. Patients with a history of regional enteritis, ulcerative colitis, or a history of C.&#xD;
             difficile associated diarrhea.&#xD;
&#xD;
          5. Patients with known current drug or alcohol abuse that could impact study compliance.&#xD;
&#xD;
          6. Patients currently receiving or who have received antifungal or antimicrobial therapy&#xD;
             (systemic or intravaginal) within 14 days of the Screening/Randomization visit.&#xD;
&#xD;
          7. Patients who have used any other investigational product within 30 days of the&#xD;
             screening/randomization visit.&#xD;
&#xD;
          8. Patients who will undergo evaluation or treatment during the study for abnormal&#xD;
             cytology and/or findings from high risk HPV testing and/or Pap test finding.&#xD;
&#xD;
          9. Patients with known sensitivity to clindamycin phosphate or other lincosamides or any&#xD;
             of the inactive ingredients in the study drug.&#xD;
&#xD;
         10. Patients with a history of any severe acute or chronic medical or psychiatric&#xD;
             condition or laboratory abnormality that could increase the risk associated with trial&#xD;
             participation or study treatment administration or could interfere with the&#xD;
             interpretation of trial results and, in the judgment of the Investigator, would make&#xD;
             the patient inappropriate for entry into the trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vision Clinical Research-Tuscon</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Age Medical Research Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research, LLC</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NuDirections Clinical Research, Inc.</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Health-Lawrence OB/GYN</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Women's Health &amp; Wellness, LLC</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jackson Clinic, PA</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <results_first_submitted>June 11, 2021</results_first_submitted>
  <results_first_submitted_qc>June 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2021</results_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04370548/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04370548/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
          <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
          <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
          <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
          <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
            <count group_id="B2" value="103"/>
            <count group_id="B3" value="307"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" spread="8.79"/>
                    <measurement group_id="B2" value="35.2" spread="8.96"/>
                    <measurement group_id="B3" value="34.8" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="307"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI, Continuous</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.75" spread="8.667"/>
                    <measurement group_id="B2" value="30.84" spread="8.183"/>
                    <measurement group_id="B3" value="31.45" spread="8.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Cure</title>
        <description>The primary efficacy endpoint is the proportion of patients with Clinical Cure at the TOC visit (Day 21-30). Clinical cure is defined as:&#xD;
Resolution of the abnormal vaginal discharge associated with BV;&#xD;
Negative 10% KOH &quot;whiff test;&quot; and&#xD;
Clue cells &lt; 20% of the total epithelial cells in the saline wet mount.</description>
        <time_frame>Visit 3 Day 21-30 post randomization</time_frame>
        <population>Clinical Cure of the mITT Population (missing data were treated as Treatment Failure)</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure</title>
          <description>The primary efficacy endpoint is the proportion of patients with Clinical Cure at the TOC visit (Day 21-30). Clinical cure is defined as:&#xD;
Resolution of the abnormal vaginal discharge associated with BV;&#xD;
Negative 10% KOH &quot;whiff test;&quot; and&#xD;
Clue cells &lt; 20% of the total epithelial cells in the saline wet mount.</description>
          <population>Clinical Cure of the mITT Population (missing data were treated as Treatment Failure)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Clinical Cure at the Interim Assessment Visit (Day 7-14).</title>
        <time_frame>Visit 2 Day 7-14 post randomization</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Clinical Cure at the Interim Assessment Visit (Day 7-14).</title>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Bacteriological Cure at the TOC Visit (Day 21-30). Bacteriological Cure is Defined as a Nugent Score &lt; 4</title>
        <time_frame>Visit 3 Day 21-30 post randomization</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Bacteriological Cure at the TOC Visit (Day 21-30). Bacteriological Cure is Defined as a Nugent Score &lt; 4</title>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Bacteriological Cure at Interim Assessment Visit, Day 7-14</title>
        <time_frame>Visit 2, Days 7-14 post randomization</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Bacteriological Cure at Interim Assessment Visit, Day 7-14</title>
          <population>mITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Therapeutic Cure at the TOC Visit (Day 21-30).</title>
        <time_frame>Visit 3 Day 21-30 post randomization</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Therapeutic Cure at the TOC Visit (Day 21-30).</title>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Therapeutic Cure at the Interim Assessment Visit (Day 7-14).</title>
        <time_frame>Visit 2 Day 7-14 post randomization</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Therapeutic Cure at the Interim Assessment Visit (Day 7-14).</title>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Patients With Clinical Cure at the Test of Cure Visit (21-30)</title>
        <time_frame>Visit 3, Days 21-30 post randomization</time_frame>
        <population>Per Protocol (PP) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Clinical Cure at the Test of Cure Visit (21-30)</title>
          <population>Per Protocol (PP) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Patients With Clinical Cure at Interim Assessment Visit, Days 7-14, PP Population</title>
        <time_frame>Visit 2, Days 7-14 post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Clinical Cure at Interim Assessment Visit, Days 7-14, PP Population</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Patients With Bacteriological Cure at Test of Cure Visit, Days 21-30, PP Population</title>
        <time_frame>Visit 3, Days 21-30 post randomization</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Bacteriological Cure at Test of Cure Visit, Days 21-30, PP Population</title>
          <population>Per Protocol Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Patients With Bacteriological Cure, Interim Assessment Visit, Days 7-14, PP Population</title>
        <time_frame>Visit 2, Days 7-14 post randomization</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Bacteriological Cure, Interim Assessment Visit, Days 7-14, PP Population</title>
          <population>PP Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Patients With Therapeutic Cure at Test of Cure Visit, Days 21-30; PP Population</title>
        <time_frame>Visit 3, Days 21-30 post randomization</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Therapeutic Cure at Test of Cure Visit, Days 21-30; PP Population</title>
          <population>PP Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Patients With Therapeutic Cure, Interim Assessment Visit, Days 7-14, PP Population</title>
        <time_frame>Visit 2, Days 7-14 post randomization</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
            <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
            <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Therapeutic Cure, Interim Assessment Visit, Days 7-14, PP Population</title>
          <population>PP Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected for the entire study duration, approximately 3.5 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clindamycin Phosphate Vaginal Gel, 2%</title>
          <description>One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) will be applied intravaginally as a single dose within 1 day of randomization.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Vaginal Gel (Universal HEC Placebo Gel)</title>
          <description>One full applicator (5 g) of placebo gel will be applied intravaginally as a single dose within 1 day of randomization.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia/High Grade Squamous Intraepithelial Lesion with features for invasion</sub_title>
                <description>HPV16</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="37" subjects_affected="35" subjects_at_risk="203"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Bacterial Vaginosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Bacterial vulvovaginitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="203"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Blood pressure incrased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Anosmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cervical friability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cervix disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vulva cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vulval disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vulvovaginal burning sensation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vulvovaginal erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="203"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP, Clinical Operations</name_or_title>
      <organization>Dare Bioscience, Inc.</organization>
      <phone>858-926-7655 ext 109</phone>
      <email>nzack@darebioscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

